ADC in vivo Efficacy Evaluation

Antibody-drug conjugates (ADCs) are under active developments as a class of highly potent biopharmaceutical agents for oncological and hematological disorder treatments. In recent years, the approval of several ADCs by FDA has inspired great investments and more advanced developments of antibody bio-conjugate therapeutics.

One important pharmacological parameter of an ADC is the in vivo efficacy that directly reflects its potency and influences clinical trial designs. As an elaborately conjugated entity, the effector activity residues in the Fc portion of the monoclonal antibody and the carried cytotoxin both contribute to the in vivo efficacy of an ADC, making the assessment more complicated. As a recognized leader in cancer immune therapy, Creative Biolabs has been supporting anti-cancer studies for decades and we fully understand and appreciate the intricacy in ADC efficacy both in vitro and in vivo. We are committed to provide the scientific community with well-established tumor models for ADC in vivo efficacy assessment. All of our animals are maintained in a clean and feed-enriched environment and related experiments are followed Institutional Animal Care and Use Committee (IACUC) approved protocols.

Animal Resources

Creative Biolabs possesses various laboratory animals including rodents (mice, rat, rabbit) and non-rodents (beagle dog and non-human primate) to support versatile demands for pre-clinical trials of new drugs. Our animal center is comprised of an enclosed animal housing facility, an animal care facility, and numerous cutting-edge equipment for animal processing. Our technical support team is led by Ph.D. level professionals with extensive knowledge and experience in all aspects of animal researches.

Animal Oncological Models

Creative Biolabs offers a diverse selections of animal oncological models for ADC efficacy assessments. The most widely used animal oncological models are xenograft models developed by transplanting human malignant cells or tissues into immunocompromised mice or other rodents. Malignant cells are usually amplified to a large number and injected into animals subcutaneously, intravenously, or orthotopically to allow tumor formation and growth.

Creative Biolabs maintains a wide variety of human cancer cell lines for xenograft tumor model development:

Condition Target Cell Line
Acute myeloid leukemia CD33 U937, THP-1, MV-4-11, TF-1a, ML-2, HL-60, L1210, K562
Pancreatic cancer CD74, CD227, nectin-4 Capan-1, Capan-2, CFPAC-1, HPAF-II, MIAPaCa-2, PANC-1
Breast cancer CD174, GPNMB, CRIPTO, nectin-4, LIV1A, HER2 Bcap-37, BT-474, ZR-751, ZR-75-30, MKN-28, NCL-N87
Ovarian cancer MUC16, TIM-1, mesothelin ES-2, HO-8910PM, PA-1, SK-OV-3
Melanoma GD2, GPNMB, ED-B, PMEL 17, endothelin B receptor A375, B16, A2058, C32, SK-MEL-30
Prostate PSMA, STEAP-1, TENB2 22Rv1, CL-1, DU145, PC-3
Renal CAIX, TIM-1 OS-RC-2, 768-O, ACHN
Mesothelioma Mesothelin
Colorectal cancer CD74, CD174, CD227, CD326, CRIPTO, FAP, ED-B COLO201, COLO205, COLO320DM, CW-2, HCT-8, HCT-15, HCT116. SW480, SW620
Lung CD56, CD326, CRIPTO, FAP, mesothelin, GD2, 5T4 NCL-H526, NCL-H1688, NCL-H69, NCL-H146, NCL-H209, NCL-H446, NCL-H226
Multiple myeloma CD56, CD74, CD138, endothelin B receptor KMS-26, RPMI-8226, KMS-11

Subcutaneous xenograft model is mostly used for pre-clinical tests. Creative Biolabs also provides genetically engineered mouse models (GEMM). In this model, tumor growth is triggered by conditional activation or inactivation of the tumor suppressive oncogene. Successful tumor formation in GEMM is selected by palpation or radiograph.

 Development processes of xenograft tumor and GEM  models in mice. Xenograft model: Subcutaneously injection of tumor cell line or  directly implantation of patient-derived tissue into immunedeficient mouse. GEM  model: mouse genetic profile is altered and leads to carcinomatous condition  and react therapeutic treatments. Development processes of xenograft tumor and GEM models in mice. Xenograft model: Subcutaneously injection of tumor cell line or directly implantation of patient-derived tissue into immunedeficient mouse. GEM model: mouse genetic profile is altered and leads to carcinomatous condition and react therapeutic treatments.

Please follow the links to find more specific information about our animal model establishment and ADC in vivo efficacy assessment for Solid Tumor and Hematological Malignancy.

Clinical Observation

After ADC administration in the model animals, we perform systematic clinical observations to assess the direct effect of ADCs. The clinical assessment, including cage-side observation and clinical check, are conduct by experienced technicians while physical parameters, such as body weight, food consumption, and physiological changes of the tested animals will be recorded and reported in detail.

Pathological Analysis

Creative Biolabs provides cutting-edge techniques and expertise in pathological evaluation. Impacts of ADC treatments in tumor cells and their effect on normal cells or tissues are visualized and analyzed in organ/tissue examinations using methods such as macroscopic assessment and immunohistochemistry.

With our technical expertise and commitment to serve the scientific community, Creative Biolabs is dedicated in providing our clients with high-quality services for the assessment of the in vivo efficacy and other in vitro or in vivo parameters of an ADC. Please contact us for more information and a detailed quote.



Related Sections

One-stop ADC Development Service: Services:
Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
*Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-381-2994
 Fax: 1-631-207-8356
 Email:

Inquiry

Top